These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20671021)

  • 1. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.
    Hyrich KL; Watson KD; Lunt M; Symmons DP;
    Rheumatology (Oxford); 2011 Jan; 50(1):117-23. PubMed ID: 20671021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
    Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K;
    Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA.
    Hamann PDH; Pauling JD; McHugh N; Hyrich K; Shaddick G;
    Rheumatology (Oxford); 2020 Jul; 59(7):1709-1714. PubMed ID: 31714580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
    Verstappen SM; Watson KD; Lunt M; McGrother K; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2010 Aug; 49(8):1570-7. PubMed ID: 20444856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
    Söderlin MK; Petersson IF; Geborek P
    Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
    Hyrich KL; Deighton C; Watson KD; ; Symmons DP; Lunt M;
    Rheumatology (Oxford); 2009 Oct; 48(10):1323-7. PubMed ID: 19706737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece.
    Sidiropoulos P; Bounas A; Athanassiou P; Koutsianas C; Petrikkou E; Kaltsonoudis E; Drosos A; Vassilopoulos D
    Clin Rheumatol; 2020 Dec; 39(12):3643-3652. PubMed ID: 32458235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity.
    Curtis JR; Chen L; Harrold LR; Narongroeknawin P; Reed G; Solomon DH
    Arthritis Care Res (Hoboken); 2010 Jan; 62(1):101-7. PubMed ID: 20191497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.